|
1
|
National Cancer Institute, . Cancer
Statistics: SEER Stat Fact Sheets: Esophageal Cancer. http://seer.cancer.gov/statfacts/html/esoph.htmlAccessed
January 1, 2014.
|
|
2
|
Gholipour C, Shalchi RA and Abbasi M: A
histopathological study of esophageal cancer on the western side of
the Caspian littoral from 1994 to 2003. Dis Esophagus. 21:322–327.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey
SM, Dong ZW, Mark SD, Qiao YL and Taylor PR: Prospective study of
risk factors for esophageal and gastric cancers in the Linxian
general population trial cohort in China. Int J Cancer.
113:456–463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tepper J, Krasna MJ, Niedzwiecki D, Hollis
D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer
R: Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu HC, Hung SK, Huang CJ, Chen CC, Chen
MJ, Chang CC, Tai CJ, Tzen CY, Lu LH and Chen YJ: Esophagectomy for
locally advanced esophageal cancer, followed by chemoradiotherapy
and adjuvant chemotherapy. World J Gastroenterol. 11:5367–5372.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karar J and Maity A: Modulating the tumor
microenvironment to increase radiation responsiveness. Cancer Biol
Ther. 8:1994–2001. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davies MA: Regulation, role, and targeting
of Akt in cancer. J Clin Oncol. 29:4715–4717. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hasselblom S, Hansson U, Olsson M, Torén
L, Bergström A, Nilsson-Ehle H and Andersson PO: High
immunohistochemical expression of p-AKT predicts inferior survival
in patients with diffuse large B-cell lymphoma treated with
immunochemotherapy. Br J Haematol. 149:560–568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong JY, Hong ME, Choi MK, Kim YS, Chang
W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, et al: The impact of
activated p-AKT expression on clinical outcomes in diffuse large
B-cell lymphoma: A clinicopathological study of 262 cases. Ann
Oncol. 25:182–188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cummins EP and Taylor CT:
Hypoxia-responsive transcription factors. Pflugers Arch.
450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jung JE, Lee HG, Cho IH, Chung DH, Yoon
SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK and Chung MH: STAT3 is
a potential modulator of HIF-1-mediated VEGF expression in human
renal carcinoma cells. FASEB J. 19:1296–1298. 2005.PubMed/NCBI
|
|
13
|
Xu Q, Briggs J, Park S, Niu G, Kortylewski
M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al:
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by
multiple oncogenic growth signaling pathways. Oncogene.
24:5552–5560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liao D and Johnson RS: Hypoxia: A key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang X, Zhu HC, Zhang C, Qin Q, Liu J, Xu
LP, Zhao LJ, Zhang Q, Cai J, Ma JX, et al: HIF-1α; 1772 C/T and
1790 G/A polymorphisms are significantly associated with higher
cancer risk: An updated meta-analysis from 34 case-control studies.
PLoS One. 8:e803962013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang X, Zhang C, Zhu HC, Qin Q, Zhao LJ,
Liu J, Xu LP, Zhang Q, Cai J, Ma JX, et al: HIF-1α P582S and A588T
polymorphisms and digestive system cancer risk-a meta-analysis.
Tumour Biol. 35:2825–2830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo Q, Dai SB, Shen F, Yu D, Shen ST,
Zhang Q, Huang JX and Wu ZD: VEGF+405G/C (rs2010963) polymorphisms
and digestive system cancer risk: A meta-analysis. Tumour Biol.
35:4977–4982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gürsel DB, ConnellAlbert YS, Tuskan RG,
Anastassiadis T, Walrath JC, Hawes JJ, Amlin-Van Schaick JC and
Reilly KM: Control of proliferation in astrocytoma cells by the
receptor tyrosine kinase/PI3K/AKT signaling axis and the use of
PI-103 and TCN as potential anti-astrocytoma therapies. Neuro
Oncol. 13:610–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dieterle A, Orth R, Daubrawa M, Grotemeier
A, Alers S, Ullrich S, Lammers R, Wesselborg S and Stork B: The Akt
inhibitor triciribine sensitizes prostate carcinoma cells to
TRAIL-induced apoptosis. Int J Cancer. 125:932–941. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kesari S, Advani SJ, Lawson JD, Kahle KT,
Ng K, Carter B and Chen CC: DNA damage response and repair:
Insights into strategies for radiation sensitization of gliomas.
Future Oncol. 7:1335–1346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pajonk F, Vlashi E and McBride WH:
Radiation resistance of cancer stem cells: The 4 R's of
radiobiology revisited. Stem Cells. 28:639–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ahmed KM and Li JJ: NF-κB-mediated
adaptive resistance to ionizing radiation. Free Radic Biol Med.
44:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C, Yang X, Zhang Q, Guo Q, He J, Qin
Q, Zhu H, Liu J, Zhan L, Lu J, et al: STAT3 inhibitor NSC74859
radiosensitizes esophageal cancer via the downregulation of HIF-1α.
Tumour Biol. 35:9793–9799. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Q, Zhang C, He J, Guo Q, Hu D, Yang
X, Wang J, Kang Y, She R, Wang Z, et al: STAT3 inhibitor stattic
enhances radiosensitivity in esophageal squamous cell carcinoma.
Tumour Biol. 36:2135–2142. 2015. View Article : Google Scholar : PubMed/NCBI
|
